Miliary tuberculosis after infliximab therapy in Lebanon [5]

Clinical Rheumatology

Volumn 23, Issue 3, 2004, Pages 279-280

  Uthman, Imad ^a   Kanj, Nadim ^a   El Sayad, Jinane ^a   Bizri, Abdul Rahman ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Infliximab; TNF inhibitors; Tuberculosis

Indexed keywords

CYCLOSPORIN; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN;

ADULT; BACTERIUM CULTURE; CASE REPORT; COUGHING; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG SURVEILLANCE PROGRAM; FEVER; HUMAN; HUMAN TISSUE; HYPERKALEMIA; INFECTION PREVENTION; LEBANON; LETTER; LUNG BIOPSY; MALE; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RISK ASSESSMENT; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; DERMATOLOGIC AGENTS; GLUCOCORTICOIDS; HUMANS; LEBANON; MALE; MYCOBACTERIUM TUBERCULOSIS; PREDNISONE; PYODERMA GANGRENOSUM; TUBERCULOSIS, MILIARY;

EID: 3042602451     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-004-0873-z     Document Type: Letter

References (6)

1. Blumberg HM, Burman WJ, Chaisson RE et al (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 67:603-62
2. Kalaajieh WK (1999) Epidemiology of tuberculosis in Lebanon. Int J Tuberc Lung Dis 3:774-777
3. Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
4. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122-2127
5. Hamilton CD (2003) Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum 48:2085-2091
6. Targeted tuberculin testing and treatment of latent tuberculosis infection (2000) This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 161(4 Pt 2):S221-247